Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Price & Analysis
Acrivon Therapeutics, Inc. Common Stock (ACRV) — MoonshotScore 29/100 (Weak band), calculated Oct 5, 2026. Price $1.99 (-0.11%), as of the Oct 5, 2026 trading session; market cap $85.2M.
Educational signal · not a buy or sell recommendation · How to read this
Acrivon Therapeutics, Inc. Common Stock · ACRV · NASDAQ
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology medicines. Their precision medicine platform aims to identify patients most likely to respond to their drug candidates.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · Acrivon Therapeutics, Inc. Common Stock (ACRV)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Fading; Momentum: Rising.
Free cash flow yield is the main valuation drag relative to sector peers.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 5 of 8
- Altman Z -2.00 · Piotroski F 1
Holding back: weak fundamentals, a rich price
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak |
The score was 29 in the stored Oct 4, 2026 snapshot and remains 29 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +4; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.99 | |
| Change on the day | -0.11% | |
| 52-week range | $1.27 – $3.56 | |
| Market capitalisation | $85.2M | |
| Price / earnings (trailing) | -0.83 | |
| Shares traded on the day | 11.2K |
Price & events
Other perspectives
Council score for Acrivon Therapeutics, Inc. Common Stock (ACRV): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ACRV film — every key number, told as a short cinematic story
~2 min · open the film
What is Acrivon Therapeutics, Inc. Common Stock (ACRV), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Acrivon Therapeutics, Inc. Common Stock (ACRV) is listed on NASDAQ. It employs 75 people and is led by Peter Blume-Jensen. In Q2 FY2026 it reported revenue of $0 and net income of -$18M. The market values it at $85.2M.
What do the latest results show for Acrivon Therapeutics, Inc. Common Stock (ACRV)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0. Against analyst estimates the company has EPS beat 5 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$18M | -$0.43 (diluted) |
| Q1 FY2026 | $0 | -$19M | -$0.49 (diluted) |
| Q4 FY2025 | $0 | -$19M | -$0.49 (diluted) |
| Q3 FY2025 | $0 | -$18M | -$0.47 (diluted) |
What are the financial strengths and risks for Acrivon Therapeutics, Inc. Common Stock (ACRV)?
Short answer
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z -2.00 · Piotroski F 1. Trailing ratios: ROE -64.4% · ROA -71.7% · current ratio 8.98 · earnings yield -124.7%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -2.00 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-64.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
How does Acrivon Therapeutics, Inc. Common Stock compare with its peers?
Short answer
Acrivon Therapeutics, Inc. Common Stock's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $7.15 Oct 5, 2026 | $564M | 94 5-pillar Oct 5, 2026 | |
| $47.76 Oct 5, 2026 | $872M | 93 5-pillar Oct 5, 2026 | |
| $10.14 Oct 5, 2026 | $591M | 91 5-pillar Oct 5, 2026 | |
| $4.63 Oct 5, 2026 | $669M | 88 5-pillar Oct 5, 2026 | |
| $4.49 Oct 5, 2026 | $879M | 85 5-pillar Oct 5, 2026 | |
| $17.11 Oct 5, 2026 | $90.6M | 83 5-pillar Oct 5, 2026 | |
| $9.73 Oct 5, 2026 | $88.2M | 77 5-pillar Oct 5, 2026 | |
| $9.81 Oct 5, 2026 | $690M | 77 5-pillar Oct 5, 2026 | |
| $4.45 Oct 5, 2026 | $184M | 76 5-pillar Oct 5, 2026 | |
| $2.69 Oct 5, 2026 | $218M | 73 5-pillar Oct 5, 2026 | |
| $2.75 Oct 5, 2026 | $222M | 68 5-pillar Oct 5, 2026 | |
| $10.91 Oct 5, 2026 | $626M | 68 5-pillar Oct 5, 2026 | |
| Acrivon Therapeutics, Inc. Common Stock (ACRV) — this page | $1.99 | $85.2M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Aug 31, 2026 (coverage not recorded)
- Transactions
- 42
- Identified insiders
- 15
- Purchases
- 0
- Sales
- 9
- Other transactions
- 33
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Acrivon Therapeutics, Inc. Common Stock (ACRV)?
- Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
- Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
- Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
- Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Common Questions About ACRV
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for ACRV?
ACRV carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology medicines.
Is ACRV a good stock to buy?
Stock Expert AI does not rate ACRV buy, sell or hold. Acrivon Therapeutics, Inc. Common Stock carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ACRV stock price today?
The last price recorded on this page for Acrivon Therapeutics, Inc. Common Stock (ACRV) is $1.99, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for ACRV?
Acrivon Therapeutics, Inc. Common Stock (ACRV) holds a MoonshotScore in the low range. Not financial advice.
How frequently does ACRV data refresh on this page?
ACRV's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ACRV's recent stock price performance?
Acrivon Therapeutics, Inc. Common Stock (ACRV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary proteomics-based patient responder identification platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACRV overvalued or undervalued right now?
Acrivon Therapeutics, Inc. Common Stock (ACRV) is loss-making, so its trailing P/E is negative (-0.83x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ACRV?
Fractional-share availability for Acrivon Therapeutics, Inc. Common Stock (ACRV) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track ACRV's earnings and financial reports?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ACRV earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 10 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.99 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T13:45:01.669Z. | |
px.change | Change on the day | -0.11% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $85.2M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T13:44:36.000Z. Captured from FMP at 2026-10-05T13:44:59.353Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -0.83 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 11.2K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$18M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 42 transactions · 0 purchases, 9 sales, 33 other transactions · 15 identified insiders · available records within the last 180 days, newest dated Aug 31, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-16 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -2.00 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
px.range52 | 52-week range | $1.27 – $3.56 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.employees | Employees | 75 | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
id.ceo | Chief executive | Peter Blume-Jensen | UNRECORDED | Stored company-profile observation — Captured 2026-10-02 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -64.4% · ROA -71.7% · current ratio 8.98 · earnings yield -124.7% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 29 of 100 · Weak · pillars 23 / 46 / 7 / 39 / 72 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.valuation_driver | Recorded valuation score driver | Free cash flow yield is the main valuation drag relative to sector peers. | OURS | Stock Expert AI MoonshotScore v2 engine · stored factor contributions | |
ours.moonshot_change | MoonshotScore movement | 29 (stored snapshot Oct 4, 2026) → 29 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.